References
- Adams, J., V. J. Palombella, E. A. Sausville, J. Johnson, A. Destree, D. D. Lazarus, J. Maas, C. S. Pien, S. Prakash, and P. J. Elliott. 1999. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 59: 2615-2622.
- Hideshima, T., P. Richardson, D. Chauhan, V. J. Palombella, P. J. Elliott, J. Adams, and K. C. Anderson. 2001. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 61: 3071-3076.
- Richardson, P. G., B. Barlogie, J. Berenson, S. Singhal, S. Jagannath, D. Irwin, S. V. Rajkumar, G. Srkalovic, M. Alsina, R. Alexanian, D. Siegel, R. Z. Orlowski, D. Kuter, S. A. Limentani, S. Lee, T. Hideshima, D. L. Esseltine, M. Kauffman, J. Adams, D. P. Schenkein, and K. C. Anderson. 2003. A phase 2 study of bortezomib in relapsed, refractory myeloma. N. Engl. J. Med. 348: 2609-2617. https://doi.org/10.1056/NEJMoa030288
- Karin, M. and A. Lin. 2002. NF-kappaB at the crossroads of life and death. Nat. Immunol. 3: 221-227.
- Rosinol, L., S. Montoto, M. T. Cibeira, and J. Blade. 2005. Bortezomib-induced severe hepatitis in multiple myeloma: a case report. Arch. Intern. Med. 165: 464-465. https://doi.org/10.1001/archinte.165.4.464
- Ghobrial, I. M. and S. V. Rajkumar. 2003. Management of thalidomide toxicity. J. Support. Oncol. 1: 194-205.
Cited by
- Boronic Acid-Containing Proteasome Inhibitors: Alert to Potential Pharmaceutical Bioactivation vol.26, pp.4, 2012, https://doi.org/10.1021/tx400032n
- The use of novel agents in multiple myeloma patients with hepatic impairment vol.11, pp.3, 2015, https://doi.org/10.2217/fon.14.270
- Injury pattern recognition to discriminate competing causes of liver injury vol.39, pp.5, 2012, https://doi.org/10.1111/liv.14056